Erasca reports RAS cancer drug data after legal threat from Revolution
After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown between the biotechs. And it did ...
April 27, 2026 04:01 PM EDTUpdated 04:16 PM R&DLaw A showdown in the clinic and the courts: Erasca and Revolution battle over RAS Nicole DeFeudis Senior Reporter Max Bayer Senior Reporter After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that